Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
Not Applicable
Recruiting
- Conditions
- Esophageal Squamous Cell CarcinomaChemoradiotherapySurvival
- Interventions
- Radiation: radiotherapy
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 320
- Registration Number
- NCT04519905
- Locations
- 🇨🇳
Fudan Universtiy Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Huadong Hospital, Shanghai, Shanghai, China
🇨🇳Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer
Phase 2
Active, not recruiting
- Conditions
- Thyroid Cancer
- Interventions
- Drug: multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 115
- Registration Number
- NCT04521348
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer
Phase 2
Completed
- Conditions
- Locally Advanced Rectal Cancer
- Interventions
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 130
- Registration Number
- NCT04518280
- Locations
- 🇨🇳
Shanghai Changhai Hospital, Shanghai, Shanghai, China
🇨🇳Zhen Zhang, Shanghai, Shanghai, China
🇨🇳Shanghai East Hospital, Shanghai, China
Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer
Phase 3
Recruiting
- Conditions
- Colorectal CancerVitamin CGLUT3
- Interventions
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 400
- Registration Number
- NCT04516681
- Locations
- 🇨🇳
Fudan university shanghai cancer center, Shanhai, Shanghai, China
Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)
Phase 2
- Conditions
- Breast Cancer
- Interventions
- Drug: Eribulin,cisplatinDrug: Gemcitabine,cisplatin
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT04517292
- Locations
- 🇨🇳
Fudan University Shanghai Cancer center, Shanghai, China
A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients
Phase 2
- Conditions
- Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 51
- Registration Number
- NCT04516655
Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Radiation: IMRT to the nasopharynx and neckDrug: Adjuvant chemotherapy with Capecitabine
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT04517214
- Locations
- 🇨🇳
Xiaomin Ou, Shanghai, China
Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 97
- Registration Number
- NCT04517305
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)
Not Applicable
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Procedure: Transcatheter Hepatic Arterial Chemoembolization (TACE)Procedure: Ablation
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT04517227
Treatment After Palbociclib-containing Regimens
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT04517318
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath